Sign In
Buy SRPT
$16.66
+0.420 (+2.59%)
At Close: Jun 04, 2026
Sarepta Therapeutics downgraded at Evercore ISI after FDA approval of gene therapy
08:21am, Friday, 23'rd Jun 2023
Sarepta Therapeutics Inc. SRPT, -2.33%, which yesterday scored a win with U.S. Food and Drug Administration approval of the first gene therapy for children with Duchenne muscular dystrophy, was downgr
Sarepta Therapeutics announces FDA approval of first gene therapy to treat Duchenne muscular dystrophy
08:09am, Friday, 23'rd Jun 2023
Sarepta Therapeutics Inc (NASDAQ:SRPT) said the US Food and Drug Administration (FDA) has accelerated approval for ELEVIDYS, its first-of-a-kind gene therapy for Duchenne muscular dystrophy (DMD). DMD
First gene therapy for deadly form of muscular dystrophy gets FDA approval for young kids
07:01pm, Thursday, 22'nd Jun 2023
WASHINGTON — The first gene therapy for a deadly form of muscular dystrophy received preliminary U.S. approval on Thursday despite concerns from some government scientists about the treatment's abil
FDA Approves Sarepta's Gene Therapy for Duchenne Muscular Dystrophy
03:43pm, Thursday, 22'nd Jun 2023
The decision marks the first approval of a gene therapy to treat DMD, a fatal and progressive disease that manifests in young children.
Sarepta Stock Yo-Yoes After Winning Highly Anticipated Gene Therapy Nod
03:05pm, Thursday, 22'nd Jun 2023
Sarepta won approval Thursday for its highly anticipated Duchenne muscular dystrophy gene therapy. SRPT stock yo-yoed in response.
Sarepta gets FDA approval for rare genetic disorder treatment
02:23pm, Thursday, 22'nd Jun 2023
Sarepta Therapeutics Inc. SRPT, +0.60% said Thursday that the Food and Drug Administration approved its Elevidys gene therapy to treat the rare genetic disorder Duchenne muscular dystrophy, or DMD. Sa
US FDA approves Sarepta's gene therapy for rare muscular dystrophy in some kids
02:17pm, Thursday, 22'nd Jun 2023
The U.S. drug regulator on Thursday granted accelerated approval to Sarepta Therapeutics' first-of-its-kind gene therapy for Duchenne muscular dystrophy (DMD), an inherited progressive muscle wasting
Sarepta Therapeutics: Value Proposition Ahead Of DMD Gene Therapy Decision
08:45am, Thursday, 22'nd Jun 2023
Sarepta Therapeutics should earn ~$1bn from its Duchenne Muscular Dystrophy franchise in 2023 - although the company has made eye-watering losses in recent years. Sarepta ought to hear any day whether
3 Small-Cap Drug Stocks to Watch as Their Clinical Trials End Soon
09:30am, Monday, 12'th Jun 2023
Major large cap pharmaceutical firms often dominate the headlines. However, small cap drug companies also contribute significantly to scientific advancements.
Frank Sands' Top 1st-Quarter Buys
03:57pm, Tuesday, 06'th Jun 2023
Sands Capital Management recently disclosed its 13F portfolio updates for the first quarter of 2023, which ended on March 31.
Why Is Sarepta Therapeutics (SRPT) Down 1.5% Since Last Earnings Report?
12:36pm, Thursday, 01'st Jun 2023
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Is Sarepta Therapeutics' Gene Therapy in Danger of Not Obtaining FDA Approval?
06:45am, Thursday, 01'st Jun 2023
The FDA has delayed its decision on Sarepta's gene therapy, SRP-9001, and investors are concerned. An approval could still be coming, but it may be narrower in scope.
Sarepta (SRPT) Down 11% on FDA Extending DMD Gene Therapy Review
03:17pm, Thursday, 25'th May 2023
The FDA extends the review period for Sarepta's (SRPT) BLA for DMD gene therapy by almost four weeks to Jun 22. The agency may limit the use of the therapy in children aged between four and five.
Why Shares of Sarepta Therapeutics Are Dropping Wednesday
01:53pm, Wednesday, 24'th May 2023
Sarepta focuses on gene therapies to treat rare diseases. SRP-9001 is designed to correct the genetic mutation that can cause Duchenne muscular dystrophy.
Sarepta Therapeutics shares fall as FDA delays decision on gene therapy
12:20pm, Wednesday, 24'th May 2023
Sarepta Therapeutics shares fell by more than 12% on the news the US Food and Drug Administration (FDA) requires more time for its review of the company's Biologics License Application (BLA) of its in
